3 Reasons Doctors Will Prefer Vaxart's Coronavirus Vaccine, and 1 Reason They Might Not

Now that Vaxart's (NASDAQ: VXRT) coronavirus vaccine candidate is concluding preclinical development and embarking on the lengthy clinical trial process, the company's chances of success are higher than ever before. While there's still some work to do before the candidate will have a chance to demonstrate its safety in a phase 1 clinical trial, the company reached an important milestone on Aug. 10 when it announced that it had filed an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA). It's impossible to know for sure whether the candidate will be effective, but potential investors should note that if the vaccine works, it just might be a favorite of clinicians and healthcare systems.